Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Wed, 01.09.2021
Polyphor AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, September 1, 2021
Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepavadin to EnBiotix
- Polyphor and EnBiotix have signed a merger agreement.
- EnBiotix acquires Inhaled Murepavadin at an agreed valuation of USD 10 million in exchange for 2'59 [ … ]
Tue, 03.08.2021
Polyphor AG
Allschwil, Switzerland, August 3, 2021
Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
- Primary endpoint of the study progression free survival (PFS) was not met
- Pre-specified interim analysis of overall survival (OS) showed no statistically significant diff [ … ]
Fri, 30.07.2021
Polyphor AG
Allschwil, Switzerland, July 30, 2021
Polyphor to extend period for its strategic evaluation by up to four weeks
Polyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation of strategic options. This review has become necessary following the negative results of the FORTRESS study for balixafortide. The board of di [ … ]
Fri, 16.07.2021
Polyphor AG
Allschwil, Switzerland, July 16, 2021
Polyphor provides update on the future of the FORTRESS study of balixafortide and announces initial restructuring steps
- The company has decided to initiate the closing of the FORTRESS study
- The company plans to analyze progression free survival (PFS) for the study including all major sub-groups given dat [ … ]
Mon, 28.06.2021
Polyphor AG
Allschwil, Switzerland, June 28, 2021
Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
- Co-primary endpoint of the study objective response rate (ORR) was not met
- The board of directors is undergoing a strategic assessment regarding the future of the company
Poly [ … ]
Tue, 08.06.2021
Polyphor AG
Allschwil, Switzerland, June 8, 2021
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist
Webinar Roundtable Being Held Thursday, June 10 @ 8amET/2pmCET
Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss bi [ … ]
Tue, 01.06.2021
Polyphor AG
Allschwil, Switzerland, June 1, 2021
Polyphor's balixafortide demonstrates consistent dual action anti-viral and anti-inflammatory activity in COVID-19 preclinical trials
- Balixafortide showed a clear anti-viral effect, different from remdesivir, in a 14-day laboratory (CPE) assay
- Balixafortide single agent treatment showed statistically sig [ … ]
Tue, 18.05.2021
Polyphor AG
Allschwil, Switzerland, May 18, 2021
Polyphor to present at the UBS Global Healthcare Virtual Conference
Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that the company will present at [ … ]
Tue, 06.04.2021
Polyphor AG
Allschwil, Switzerland, April 6, 2021
Polyphor Annual General Meeting 2021
Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the 24th Annual General Meeting (AGM) with a significant majority, with the exception of the proposed increase of the conditional capital for the employee stoc [ … ]
Tue, 05.01.2021
Polyphor AG
Allschwil, Switzerland, January 5, 2021
Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Co [ … ]